Moderna's Cancer Vaccine Could Change America in 7 Surprising Ways
Newsweek · C · trust 62/100
0 Share Newsweek is a Trust Project member See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A breakthrough cancer vaccine developed by Moderna and Merck is fueling hopes that the next revolution in medicine could be as transformative as the arrival of antibiotics, organ transplants or the first targeted cancer drugs.
Moderna and Merck announced this week that their Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with high-risk melanoma whose tumors had been surgically removed. The treatment being studied, intismeran autogene, is a personalized mRNA therapy tailored to each patient's tumor and administered alongside Merck's immunotherapy Keytruda. The companies said the results represent the first positive Phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer therapy.
The data will be presented at an upcoming international medical meeting, a Moderna spokesperson told Newsweek .
"Pending regulatory feedback, intismeran could be available as soon as next year," the spokesperson said.
While the vaccine has so far demonstrated positive Phase 3 results only in melanoma, Merck and Moderna are also studying the personalized mRNA therapy in several other cancers, including non-small cell lung cancer, bladder cancer and kidney cancer. Whether the approach can deliver similar benefits in those diseases remains the subject of ongoing clinical trials.
Although the treatment is still experimental and has demonstrated a positive Phase 3 result only in melanoma so far, the findings are being viewed as a potential proof of concept for a new method of cancer treatment. Unlike traditional therapies that are the same for every patient, intismeran autogene is custom-built using the unique mutations found in an individual's tumor. If ongoing studies in other cancers produce similar results and regulators ultimately approve the vaccine, the technology could influence far more than cancer care itself, potentially changing how treatments are developed, manufactured and delivered across the U.S. healthcare system.
For decades, cancer treatment has largely focused on removing tumors and preventing them from returning. Personalized cancer vaccines introduce a different possibility: keeping patients cancer-free for much longer after initial treatment.
If future studies confirm similar benefits in other cancers, personalized cancer vaccines could help some patients remain cancer-free for longer periods after treatment, though researchers are still studying the long-term impact on survival and disease recurrence.
"We need better ways to prevent recurrence for patients in remission. Recurrence of cancer is a most dreaded event," Dr. Robert Vonderheide, director of the Abramson Cancer Center at Penn Medicine and president-elect of the American Association for Cancer Research, told Newsweek . "A vaccine to mobilize the immune system to guard against recurrence would be a gamechanger. This news means such a vaccine is probably closer to reality than we thought."
Doctors already manage diseases such as HIV and diabetes through long-term treatment strategies, and cancer could begin moving in a similar direction for certain patients. The melanoma trial's success has intensified hopes that durable immune protection may become a central part of cancer care.
Every dose of intismeran autogene is uniquely designed for an individual patient.
Unlike traditional medicines that are manufactured identically for millions of people, the therapy is built from the genetic fingerprint of a patient's own tumor. Moderna says the vaccine can encode up to 34 tumor-specific targets, effectively creating a highly customized treatment. The success of the melanoma program may accelerate a broader shift toward personalized medicine, in which therapies are increasingly generated from a person's genetic information rather than selected from a standard list of drugs.
"This vaccine is just one of many vaccines – some similar, others with different approaches – that will soon be delivering clinical results," Vonderheide said. "There is every reason for excitement and hope as we enter what feels like a new stage of cancer immunotherapy."
Personalized medicine could drive greater use of artificial intelligence (AI) in cancer care. Scientists are already studying how AI can help identify tumor-specific mutations and select promising neoantigens for personalized cancer vaccines. If individualized treatments become more common, healthcare systems may increasingly rely on advanced computing tools to process the genetic information needed to develop and guide those therapies.
"The individualized nature of this mRNA vaccine is very promising, because as cancers grow, they can evolve and create new mutations that make them more aggressive," Dr. Christina Annunziata, senior vice president of extramural discovery at the American Cancer Society, told Newsweek . "And, not everyone will have the exact same set of mutations in their cancer. This technology takes the DNA from the patient’s own tumor cells, sequences it to find mutations, and compares it to the DNA sequences from their non-cancer cells. A computer algorithm then uses this information to select up to 34 different mutated gene fragments which are then made into RNA and incorporated into the personalized vaccine."
Personalized cancer vaccines are significantly more complex than conventional drugs.
Because the therapy is individually designed using mutations identified within a patient's tumor, it differs from traditional cancer treatments that are manufactured the same way for every patient. If approved, the approach could require new clinical and manufacturing workflows to produce personalized therapies at scale.
Personalized cancer vaccines require tumor sequencing,…
Read the original at Newsweek →
Open in TruthVane →